Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Other Infectious Diseases
Conditions
Other Infectious Diseases
Trial Timeline
May 16, 2018 → Feb 16, 2022
NCT ID
NCT03485950About Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam is a phase 2 stage product being developed by Merck for Other Infectious Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03485950. Target conditions include Other Infectious Diseases.
What happened to similar drugs?
4 of 20 similar drugs in Other Infectious Diseases were approved
Approved (4) Terminated (4) Active (13)
🔄recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03485950 | Phase 2 | Completed |
Competing Products
20 competing products in Other Infectious Diseases